Document Detail

Pivotal results for the Medtronic Valiant Thoracic Stent Graft System in the VALOR II trial.
MedLine Citation:
PMID:  22832267     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: We report 30-day and 12-month results of endovascular treatment with the Valiant Thoracic Stent Graft System (Medtronic Vascular, Santa Rosa, Calif) in patients with descending thoracic aortic aneurysms of degenerative etiology. The Valiant stent graft is an evolution of the Talent thoracic stent graft (Medtronic Vascular).
METHODS: The VALOR II (Evaluation of the Clinical Performance of the Valiant Thoracic Stent Graft System in the Treatment of Descending Thoracic Aneurysms of Degenerative Etiology in Subjects Who Are Candidates for Endovascular Repair) was a prospective, nonrandomized, pivotal trial conducted at 24 U.S. sites with enrollment between December 2006 and September 2009. Standard follow-up examinations, including physical examination, computed tomography, and chest radiography, were at 1, 6, and 12 months, and annually through 5 years. VALOR II outcomes were compared with those from the pivotal VALOR (Evaluation of the Medtronic Vascular Talent Thoracic Stent Graft System for the Treatment of Thoracic Aortic Aneurysms) trial of the Talent stent graft, which enrolled 195 patients with similar enrollment criteria.
RESULTS: VALOR II enrolled 160 patients. Compared with VALOR patients, VALOR II patients had similar age and sex distribution but higher rates of cardiovascular risk factors and significantly more severe modified Society for Vascular Surgery/American Association for Vascular Surgery risk scores. Stent graft delivery and deployment were successful in 154 patients (96.3%). Outcomes at 30 days in VALOR II were perioperative mortality, 3.1%; major adverse events, 38.1%; paraplegia, 0.6%; paraparesis, 1.9%; and stroke, 2.5%. At 12 months, after the minimum sample size was reached, 151 patients were evaluated: aneurysm-related mortality was 4.0%, stent graft migration was 2.9%, and endoleak was 13.0%. Through 12 months, there were no ruptures, conversions to open surgery, secondary procedures due to endoleak >30 days, or loss of stent graft patency. The Valiant stent graft was statistically noninferior to the Talent stent graft in 12-month all-cause mortality (12.6% vs 16.1%) and exceeded the primary effectiveness goal of 12-month successful aneurysm treatment, defined as absence of aneurysm growth >5 mm and of secondary procedures for type I/III endoleak (97.4% vs 80.0%).
CONCLUSIONS: The VALOR II 12-month results demonstrate that the Medtronic Valiant thoracic stent graft is a safe and effective treatment for patients with descending thoracic aortic aneurysms of degenerative etiology.
Ronald M Fairman; J Michael Tuchek; W Anthony Lee; Karthikeshwar Kasirajan; Rodney White; Manish Mehta; Sean Lyden; Dipankar Mukherjee; Joseph Bavaria;
Related Documents :
12584387 - Principle mechanisms underlying venous thromboembolism: epidemiology, risk factors, pat...
9988957 - Issues and controversies in venous thromboembolism.
2356977 - Clinical study of late-stage postthrombotic lower extremities.
17372167 - Mutations in foxc2 are strongly associated with primary valve failure in veins of the l...
9663197 - Minimally invasive direct coronary artery bypass--a surgical approach for anomalous rig...
20471787 - Successful repair for a ruptured venous aneurysm: an unusual complication of venous art...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't     Date:  2012-07-24
Journal Detail:
Title:  Journal of vascular surgery     Volume:  56     ISSN:  1097-6809     ISO Abbreviation:  J. Vasc. Surg.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-10-22     Completed Date:  2012-12-31     Revised Date:  2013-02-06    
Medline Journal Info:
Nlm Unique ID:  8407742     Medline TA:  J Vasc Surg     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1222-31.e1     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.
Hospital of the University of Pennsylvania, Philadelphia, Pa 19104, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aortic Aneurysm, Thoracic / surgery*
Endovascular Procedures*
Prospective Studies
Prosthesis Design
Comment In:
Expert Rev Cardiovasc Ther. 2013 Jan;11(1):27-30   [PMID:  23259442 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Attenuation of spinal cord ischemia-reperfusion injury by specific ?-2a receptor activation with dex...
Next Document:  Staged hybrid approach using proximal thoracic endovascular aneurysm repair and distal open repair f...